Polypharmacotherapy in older age – drug interactions of the most frequently prescribed drugs in cardiology

Česká verzia

Authors: H. Matějovská Kubešová; K. Bielaková; O. Výška; S. Surková; D. Prudius; K. Greplová
Authors place of work: Klinika interní, geriatrie a praktického lékařství LF MU a FN Brno
Published in the journal: Kardiol Rev Int Med 2018, 20(1): 22-28

Summary

The authors stress the specific characteristics of the older population – increasing number of diseases and increasing number of medications used, higher risk of unwanted side effects and drug interactions. Higher number of medicaments usually means lower adherence by patients. This situation needs a simple and safe final medication scheme. If the ability of older patients to take the medications correctly decreases, it is necessary to provide them with assistance. The development of safety criteria is mentioned – starting with Beers criteria up to the currently-used STOPP-START criteria. The most frequently used medicaments are discussed – angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers, diuretics and statins. The final part of the article deals with the relationship between the loss of self-sufficiency and the resulting risks for the safety of pharmacotherapy. The article is completed with a table containing basic principles of drug prescription for elderly patients.

Key words:
polymorbidity – polypharmacotherapy – drug interactions – undesired side effects – adherence – self-sufficiency – cognitive decline

Zdroje

1. Wenger NK, Doherty CL, Gurwitz JH et al. Optimization of drug prescription and medication management in older adults with cardiovascular disease. Drugs Aging 2017; 34(11): 803– 810. doi: 10.1007/ s40266-017-0494-2.

2. Vepřeková B. Respekt k autonomii geriatrického pacienta: kognitivní a mnestická kapacita. Dizertační práce. Brno: LF MU 2012.

3. Lozano I, Sanchez-Insa E, de Leiras SR. Acute coronary syndromes, gastrointestinal protection, and recommendations regarding concomitant administration of proton-pump inhibitors (omeprazol/ esomeprazole) and clopidogrel. Am J Cardiol 2016; 117(3): 366– 368. doi: 10.1016/ j.amjcard.2015.11.007.

4. Rappaport R, Arinzon Z, Feldman J et al. The need for medication reconciliation increases with age. Isr Med Assoc J 2017; 19(10): 625– 630.

5. Bailey DG, Spence JD, Edgar B et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12(6): 357– 362.

6. Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens 2006; 19(7): 768– 773.

7. Beers MH, Ouslander JG, Rollingher I et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151(9): 1825– 1832.

8. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14): 1531– 1536.

9. Fick DM, Cooper JW, Wade WE et al. Updating the beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003; 163(22): 2716– 2724.

10. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60(4): 616– 631. doi: 10.1111/ j.1532-5415.2012.03923.x

11. McLeod PJ, Huang AR, Tamblyn RM et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 1997; 156(3): 385– 391.

12. Gallagher P, Ryan C, Byrne S et al. STOPP (Screeening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Int J Clin Pharmacol Ther 2008; 46(2): 72– 83.

13. Topinková E, Mádlová P, Fialová D et al. Nová evidence-based kritéria pro posouzení vhodnosti lékového režimu u seniorů. Kritéria STOPP (Screening Tool of Older Person’s Prescriptions) a START (Screening To ol to Alert doctors to Right Tre atment). Vnitř Lék 2008; 54(12): 1161– 1169.

14. Fialová D, Topinková E, Matějovská Kubešová H et al. Racionální farmakoterapie ve stáří: Expertní konsensus ČR 2012 v oblasti léčiv a lékových postupů potenciálně nevhodných u seniorů. Geriatrie a gerontologie 2013; 2(1): 5– 15.

15. O’Mahony D, O’Sullivan D, Byrne et al. STOPP/ START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015; 44(2): 213– 218. doi: 10.1093/ ageing/ afu145.

16. Foppiani L, Cascio C, Lo Pinto G. Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly. Aging Clin Exp Res 2016; 28(5): 1023– 1027. doi: 10.1007/ s40520-015-0483-4.

17. Taylor BA, Lorson L, White CM et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015; 238(2): 329– 335. doi: 10.1016/ j.atherosclerosis.2014.12.016.

18. Konopa J, Bullo B, Rutkowski B. Life threatening drug-induced hyperkaliemia – case report. Pol Arch Med Wewm 2006; 115(3): 238– 242.

19. Woolcott JC, Richardson KJ, Wiens MO. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169(21): 1952– 1960. doi: 10.1001/ archinternmed.2009.357.

20. Galinier M, Emeriau JP. Prescribing beta blockers in elderly patients with heart failure. Presse Med 2008; 37 (6 Pt 2): 1047– 1054. doi: 10.1016/ j.lpm.2008.02.011.

21. Cleland JG, Coletta AP, Torabi A et al. Clinical trials update from the European Society of Cardiology Heart Failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF. Eur J Heart Fail 2009; 11(8): 802– 805. doi: 10.1093/ eurjhf/ hfp102.

22. Wikstrand J, Wedel H, Castagno D et al. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med 2014; 275(2): 134– 143. doi: 10.1111/ joim.12141.

23. Edelmann F, Musial-Bright L, Gelbrich G et al. Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: Insights from the CIBIS-ELD Trial. JACC Heart Fail 2016; 4(2): 140– 149. doi: 10.1016/ j.jchf.2015.10.008.

24. Axmon A, Ahlström G, Höglund P. Prevalence and treatment of diabetes mellitus and hypertension among older adults with intellectual disability in comparison with the general population. BMC Geriatr 2017; 17(1): 272. doi: 10.1186/ s12877-017-0658-2.

25. van Middelaar T, van Vught LA, van Charante EP et al. Lower dementia risk with different classes of antihypertensive medication in older patients. J Hypertens 2017; 35(10): 2095– 2101. doi: 10.1097/ HJH.0000000000001411.

26. Rouch L, Cestac P, Hanon O el al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs 2015; 29(2): 113– 130. doi: 10.1007/ s40263-015-0230-6.

27. Kalvach Z, Zadák Z, Jirák R et al. Geriatrie a gerontologie. Praha: Grada Publishing 2004.

28. Woodward M, Gonski P, Grossmann M et al. Diag-nosis and management of hyponatraemia in the older patient. Intern Med J 2018; 48 (Suppl 1): 5– 12. doi: 10.1111/ imj.13682.

29. Spinar J, Parenica J, Vitovec J et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care 2011; 15(6): R291. doi: 10.1186/ cc10584.

30. Llobet Vila L, Manresa Domínguez JM, Carmona Segado JM. Facing a dilemma in elderly complex and vulnerable patients: to stop or not to stop prevention? Aten Primaria 2017; pii: S0212-6567(17)30174-9. doi: 10.1016/ j.aprim.2017.05.016.

31. Kriegbaum M, Lau SR. Medication non-adherence and uncertainty: Information-seeking and processing in the Danish LIFESTAT survey. Res Social Adm Pharm 2017; pii: S1551-7411(17)30571-5. doi: 10.1016/ j.sapharm.2017.09.002.

32. Riaz H, Krasuski RA. Should physicians be encouraged to use generic names and to prescribe generic drugs? Am J Cardiol 2016; 117(11): 1851– 1852. doi: 10.1016/ j.amjcard.2016.03.023.

33. Hennein R, Hwang SJ, Au R et al. Barriers to medication adherence and links to cardiovascular disease risk factor control: the Framingham Heart Study. Intern Med J 2017. doi: 10.1111/ imj.13687.

34. Stacey E. Hot topics in General Practice. Oxford: BIOS Scientific Publishers 1996.